<DOC>
	<DOC>NCT01595932</DOC>
	<brief_summary>The aim of this study was to evaluate the efficacy and tolerability of α-galactosidase in pediatric patients with predominant gas-related symptoms.</brief_summary>
	<brief_title>Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children</brief_title>
	<detailed_description>Most patients with functional gastrointestinal disorders complain of gas-related symptoms which can negatively affect quality of life, even in pediatric age. Dietary and life-style changes, administration of simethicone, activated charcoal and probiotics may reduce intestinal gas but often results are unsatisfactory. Literature shows that α-galactosidase is effective to reduce gas production and related symptoms in adults.</detailed_description>
	<criteria>pediatric outpatients with gasrelated disturbances at least once per week over the last 12 weeks. suspected episodes of hypersensitivity or allergy; chronic organic disorders (by clinical history, physical examination, laboratory tests); use of drug affecting the GI motility during the previous 4 weeks; inability of the parent to comprehend the full nature and purpose of the study and unwillingness to cooperate with the Investigator.</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>irritable bowel syndrome (IBS)</keyword>
	<keyword>bloating</keyword>
	<keyword>abdominal distension</keyword>
	<keyword>flatulence</keyword>
	<keyword>α-Galactosidase</keyword>
</DOC>